Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) announced that its independent Compensation Committee approved inducement option awards for eight non-executive employees totaling 451,448 options, approved on November 14, 2025.

The options have a 10-year term, an exercise price of $13.02 per share (Crescent's Nasdaq closing price on November 14, 2025), and vest 25% on the first anniversary of each employee's start date with the remainder vesting 1/48th monthly thereafter, subject to continuous service and the Inducement Plan terms. The grants were described as material to each employee's acceptance under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

-0.54%

1 alert

-0.54% News Effect

On the day this news was published, CBIO declined 0.54%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 451,448 shares of the Company’s ordinary shares to eight non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on November 14, 2025 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $13.02, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on November 14, 2025. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contact

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

FAQ

How many options did Crescent Biopharma grant on November 14, 2025 for Nasdaq: CBIO?

The company granted an aggregate of 451,448 options to eight non-executive employees.

What is the exercise price and term of the CBIO inducement options granted November 14, 2025?

Each option has an exercise price of $13.02 and a 10-year term from the grant date.

What is the vesting schedule for the CBIO inducement awards granted in November 2025?

Options vest 25% on the first anniversary of each employee’s start date, then 1/48th monthly thereafter, subject to continuous service.

Why did Crescent Biopharma say the options were granted under Nasdaq Listing Rule 5635(c)(4)?

The grants were approved as equity inducement awards and were described as material to each employee’s acceptance, consistent with Nasdaq Listing Rule 5635(c)(4).

Who received the inducement awards announced by Crescent Biopharma on November 17, 2025?

The awards were granted to eight non-executive employees as inducement equity under the 2025 Inducement Incentive Award Plan.